73 annotations
Page 3 of 4
in diagnostics and healthcare in Q3, revenue was approximately 20% lower
(No comment added)
Transcript
2023 Q3
17 Nov 23
industrial and applied, growth was flat for the third quarter.
(No comment added)
Transcript
2023 Q3
17 Nov 23
academic and government, we grew in the high single digits
(No comment added)
Transcript
2023 Q3
17 Nov 23
pharma and biotech
(No comment added)
Transcript
2023 Q3
17 Nov 23
The COVID-19 vaccine and therapy revenue runoff
(No comment added)
Transcript
2023 Q3
17 Nov 23
We now expect revenue to be $42.7 billion and adjusted EPS to be $21.50 per share
(No comment added)
Transcript
2023 Q3
17 Nov 23
we continue to expect to grow faster than the market for the full year and to once again deliver share gain in 2023
(No comment added)
Transcript
2023 Q3
17 Nov 23
we now expect core market growth to be slightly negative for the year.
(No comment added)
Transcript
2023 Q3
17 Nov 23
cautious customer spending and low economic activity in China.
(No comment added)
Transcript
2023 Q3
17 Nov 23
adjusted EPS, achieving a 12% increase to $5.69 per share
(No comment added)
Transcript
2023 Q3
17 Nov 23
expanded our adjusted operating margin 200 basis points to 24.2%
(No comment added)
Transcript
2023 Q3
17 Nov 23
adjusted operating income grew 8%
(No comment added)
Transcript
2023 Q3
17 Nov 23
The company’s adjusted gross margin in the quarter came in at 41.7%, 970 basis points lower than Q3 last year.
(No comment added)
Transcript
2022 Q3
1 Nov 22
We now expect net capital expenditures of approximately $2.3 billion to $2.5 billion.
For free cash flow, we see $7 billion at the high end of the range of outcomes for the year. The actual free cash flow will depend on the year-end level of working capital.
(No comment added)
Transcript
2022 Q3
1 Nov 22
FX in 2023 would be a year-over-year headwind of approximately $1 billion on revenue and $0.75 on adjusted EPS.
(No comment added)
Transcript
2022 Q3
1 Nov 22
The FX headwind on adjusted EPS in 2022 is now expected to be $0.77 for the full year or 3.1%
(No comment added)
Transcript
2022 Q3
1 Nov 22
we now expect FX to be a year-over-year headwind of $1.46 billion on revenue or 3.7%
(No comment added)
Transcript
2022 Q3
1 Nov 22
We now expect the business to contribute $2.03 to adjusted EPS in the year, up $0.03 from our prior guidance.
(No comment added)
Transcript
2022 Q3
1 Nov 22
The impact on margins for the full year from this dynamic is about 60 basis points
(No comment added)
Transcript
2022 Q3
1 Nov 22
we’ve been very effective in passing on higher price to offset higher-than-normal inflation. This results in no net impact on our adjusted operating income dollars as we’re effectively offsetting the added inflation, but it does affect the calculation of margins because of the revenue base being higher
(No comment added)
Transcript
2022 Q3
1 Nov 22